<DOC>
	<DOCNO>NCT02502669</DOCNO>
	<brief_summary>Double-blind , randomize , placebo-controlled , dose-ranging study evaluate efficacy safety weekly , high dose oral finasteride compare placebo treatment severe nodulocystic acne male subject .</brief_summary>
	<brief_title>Finasteride Treatment Severe Nodulocystic Acne</brief_title>
	<detailed_description>There 180 male subject study . The study compose Screening Period 30 day inclusion / exclusion criterion review , screen laboratory result obtain medication washout do require . Subjects complete sexual function questionnaire depression scale . A one day Baseline Period ( Day 0 ) , baseline assessment acne lesion count , physical examination Investigator 's Global Assessment Scale do . The Baseline Period follow 12-week randomized double-blind Treatment Period , subject randomize Finasteride 23.5 mg group , 33.5 mg group , placebo group . During Treatment Period , subject visit study site Day 14 , Day 28 , Day 56 acne lesion count review diary , concomitant medication adverse event . On Day 84 subject return clinic acne lesion count review diary , concomitant medication , adverse event remain study drug count collect . A physical exam vital sign , Investigator Global Assessment , Subject Assessment Efficacy , depression scale sexual function questionnaire complete subject discharge study .</detailed_description>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Subject voluntarily agree participate study sign IRBapproved inform consent prior perform screen procedure . 2 . Males 18 year 35 year age . 3 . Except severe nodulocystic acne , subject generally good health . 4 . Ten ( 10 ) nodular lesion ( facial and/or truncal ) . 5 . Weight 40 110 kg . 6 . No significant disease clinically significant find physical examination . 7 . No clinically significant abnormal laboratory value . 8 . No clinically significant abnormal vital sign measurement . 9 . Subject able swallow pill . 10 . Subject agree use medically acceptable form barriermethod contraception ( e.g . condom spermicide abstinence ) . 11 . Subject willing able cooperate extent require protocol . 1 . Female subject exclude study . 2 . Subject acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc . ) , pyoderma faciale , sinus track . 3 . Subject wash period Baseline topical treatment skin le : Corticosteroids , antibiotic , antibacterial , antiseptic , retinoids , antiinflammatory drug acne treatment ( 2 week ) ; Cosmetic procedure ( 1 week ) ; Photodynamic therapy laser therapy acne ( 3 month ) . 4 . Subject washout period Baseline systemic treatment le : Corticosteroids , antibiotic ( 4 week ) , spironolactone ( 3 month ) , systemic acne treatment ( 6 month ) , cyproterone acetate ( 6 month ) , lithium , anticonvulsant , barbiturate , androgenic anabolic steroid , testosterone , estrogen , antituberculous drug , cyclosporine , azathioprine ( 6 month ) , surgical treatment acne ( 12 month ) , finasteride 5α−reductase inhibitor ( 12 month ) . ( Table 2 ) 5 . Subjects current history prostatic disease include benign prostatic hypertrophy , surgery prostate . 6 . Known history presence clinically significant unstable medical condition ( ) opinion investigator could pose risk safety subject , e.g . diabetes , cardiovascular , liver kidney disease . 7 . Subjects skin disease condition might interfere evaluation nodular acne . 8 . Known history suspect carcinoma . 9 . Allergy finasteride ingredient study medication . 10 . Subjects history past 12 month active addiction , abuse , misuse and/or dependence drug alcohol . 11 . Use investigational drug within 90 day prior Day 1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acne</keyword>
	<keyword>nodulocystic</keyword>
	<keyword>finasteride</keyword>
	<keyword>5 alpha reductase inhibitor</keyword>
</DOC>